{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-009345","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.872503+00:00","generated_at":"2026-06-17T12:33:53.234359+00:00","sec_items":["2.02","9.01","5.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aadi Bioscience reports FY2022 revenue $15.2M; PRECISION-1 data Q2 2023","bullets":["FY 2022 total revenue $15.2M from FYARRO (10 months); Q4 net product sales $5.2M (+23% QoQ).","Net loss $60.5M for FY2022 vs $110.1M in FY2021 (prior year incl $74.2M impairment).","Cash $172.6M at Dec 31, 2022; cash runway into 2025 after $72.5M Q4 financing.","PRECISION-1 trial preliminary data on TSC1/TSC2 alterations expected Q2 2023.","Appointed Dr. Mohammad Hirmand to Board; collaboration with Mirati on adagrasib combo trial start Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-009345","json":"https://secwatch.observer/filing/0001628280-23-009345.json","markdown":"https://secwatch.observer/filing/0001628280-23-009345.md","text":"https://secwatch.observer/filing/0001628280-23-009345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/0001628280-23-009345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/aadi-20230324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:33:53.234359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a412466f5948b73977aad1663cab2226890ccece","claim":"Whitehawk Therapeutics, Inc. reported Fiscal year ended December 31, 2022 results: revenue $15.2 million, net income $60.5 million net loss.","evidence_excerpt":"Total revenue for the quarter ended December 31, 2022 was $5.2 million, and $15.2 million for the full-year ended December 31, 2022, resulting from sales of FYARRO. • Net loss for the three months ended December 31, 2022 was $13.9 million as compared to $16.0 million for the three months ended December 31, 2021. Net loss for the full-year 2022 ended December 31, 2022 was $60.5 million, as compared to $110.1 million for the period in 2021 (The prior year included the non-cash impairment charge of $74.2 million related to the acquired contract intangible asset incurred in conjunction with the Aerpio merger).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/0001628280-23-009345-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$15.2 million"},{"label":"Net income","value":"$60.5 million net loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"daa871a4d8927b3e357c28ecdbfab16465114f08","claim":"Whitehawk Therapeutics, Inc. reported Three months ended December 31, 2022 results: revenue $5.2 million, net income $13.9 million net loss.","evidence_excerpt":"Total revenue for the quarter ended December 31, 2022 was $5.2 million, and $15.2 million for the full-year ended December 31, 2022, resulting from sales of FYARRO. • Net loss for the three months ended December 31, 2022 was $13.9 million as compared to $16.0 million for the three months ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/0001628280-23-009345-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Three months ended December 31, 2022"},{"label":"Revenue","value":"$5.2 million"},{"label":"Net income","value":"$13.9 million net loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"23edf8b39a","claim":"Mohammad Hirmand was appointed as Class II Director at Whitehawk Therapeutics, Inc..","evidence_excerpt":"On March 24, 2023, Mohammad Hirmand, M.D. was appointed a Class II director by the Board of Directors (the “ Board ”) of the Company, effective March 27, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/0001628280-23-009345-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}